ERBB2 and cancer: In a large-scale phase-I/II multi-center study (Kumthekar et al., 2023), HER-2-positive histological cancer patients were included in the phase-I study, and the maximum tolerable dose for IT trastuzumab was determined to be 80 mg, twice a week, while ensuring both treatment effectiveness and safety.